JAK inhibitors, which primarily inhibit JAK1 and JAK2, are garnering attention as new therapeutic agents for atopic dermatitis. These drugs exert a favorable therapeutic effect by blocking the intracellular signaling of multiple cytokines involved in the pathogenesis of atopic dermatitis, such as IL-4, IL-13, IL-22, and thymic stromal lymphopoietin. Additionally, they are unlikely to cause serious side effects, even when systemically administered, because they have a little effect on molecules in the JAK family except JAK1 and JAK2. One of the clinical characteristics of JAK inhibitors is their ability to rapidly exert their effect after their administration. The administration of JAK inhibitors can reduce the itching sensation within a few days. Notably, this effect does not diminish even in cases where they are administered for an extended period; however, the effect quickly dissipates after discontinuation of their administration. Until June 2023, three orally administered JAK inhibitors were available in Japan to treat atopic dermatitis; however, these inhibitors are expensive. Nevertheless, their high therapeutic responsiveness can be utilized for remission induction in patients with moderate to severe disease or used to deliver adjunctive therapy to topical steroids in acute exacerbations.